Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Pharmacology

60%

Oncology

100%

Targeted Therapy

70%

Adjuvant Therapy

60%

Cancer Biology

60%

Neoadjuvant Therapy

50%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Article Link

Year:

2024

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Article Link

Year:

2024

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Article Link

Year:

2024

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

Article Link

Year:

2024

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Article Link

Year:

2023

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Article Link

Year:

2023

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

Article Link

Year:

2023

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Article Link

Year:

2023

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Article Link

Year:

2023

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Article Link

Year:

2023

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Article Link

Year:

2022

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Article Link

Year:

2022

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Article Link

Year:

2022

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

Article Link

Year:

2021

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Article Link

Year:

2021

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Article Link

Year:

2021

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

Article Link

Year:

2021

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Article Link

Year:

2021

Collaborators10

Bartomeu Massuti

Head Department

Istituto Europeo di Oncologia

SPAIN

Ana Arance

University of Barcelona

SPAIN

Rosalyn Juergens

CANADA

Mario Sznol

Professor, Internal Medicine

Yale University Yale Cancer Center

UNITED STATES

Keith Eaton

Fred Hutchinson Cancer Research Center

UNITED STATES

Hans-Georg Kopp

Head of Department

Robert Bosch Center for Tumor Diseases

GERMANY

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES

Mariano Provencio Pulla

Head of Medical Oncology Department at Puerta de Hierro University Hospital

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

Joaquim Bosch-Barrera

Professor Associat Doctor

Universitat de Girona

SPAIN

Javier De Castro

HEAD OF LUNG CANCER UNIT

La Paz University Hospital

SPAIN

How do I reach out?

Meet Kite AI